CareDx, Inc
CDNANASDAQHealthcare● Active
$22.26
+$0.01(+0.04%)
Market Cap$1.1B
P/E Ratio—
52W High$23.24
52W Low$10.96
CareDx, Inc (CDNA) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
CDNA · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: Apr 28, 2026EPS Actual
$0.34
Est. $0.11 · +209.1%
Revenue
$0.12B
Est. $0.10B · +15.4%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
Apr 28, 2026
After Market Close
▲ Beat EPS▲ Beat Revenue✓ 3-Quarter EPS Beat Streak
CDNA reports quarterly as a NASDAQ-listed Medical - Diagnostics & Research company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Rev. $0.58B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
Rev. Est.$0.58B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 5, 2026 | $0.22 | — | — | — | $0.11B | — |
| ▲ Q2 FY2026 | Apr 28, 2026 | $0.11 | $0.34 | +209.1% | $0.12B | $0.10B | +15.4% |
| ▲ Q1 FY2026 | Feb 24, 2026 | $0.02 | $0.12 | +503.0% | $0.11B | $0.10B | +5.0% |
| ▲ Q4 FY2025 | Nov 4, 2025 | $0.13 | $0.28 | +115.4% | $0.10B | $0.10B | -2.6% |
| ▼ Q3 FY2025 | Aug 6, 2025 | $0.12 | $0.10 | -16.7% | $0.09B | $0.10B | -9.0% |
| ▲ Q2 FY2025 | Apr 30, 2025 | $0.06 | $0.09 | +50.0% | $0.08B | $0.08B | +0.2% |
| ▲ Q1 FY2025 | Feb 26, 2025 | $0.05 | $0.18 | +260.0% | $0.09B | $0.08B | +2.4% |
| ▲ Q4 FY2024 | Nov 4, 2024 | $0.01 | $0.14 | +1300.0% | $0.08B | $0.08B | +0.9% |
Q3 FY2026
Aug 5, 2026
EPS Actual
—
EPS Est.
$0.22
EPS Surpr.
—
Revenue
—
Q2 FY2026
Apr 28, 2026Beat
EPS Actual
$0.34
EPS Est.
$0.11
EPS Surpr.
+209.1%
Revenue
$0.12B
Q1 FY2026
Feb 24, 2026Beat
EPS Actual
$0.12
EPS Est.
$0.02
EPS Surpr.
+503.0%
Revenue
$0.11B
Q4 FY2025
Nov 4, 2025Beat
EPS Actual
$0.28
EPS Est.
$0.13
EPS Surpr.
+115.4%
Revenue
$0.10B
Q3 FY2025
Aug 6, 2025Miss
EPS Actual
$0.10
EPS Est.
$0.12
EPS Surpr.
-16.7%
Revenue
$0.09B
Q2 FY2025
Apr 30, 2025Beat
EPS Actual
$0.09
EPS Est.
$0.06
EPS Surpr.
+50.0%
Revenue
$0.08B
Q1 FY2025
Feb 26, 2025Beat
EPS Actual
$0.18
EPS Est.
$0.05
EPS Surpr.
+260.0%
Revenue
$0.09B
Q4 FY2024
Nov 4, 2024Beat
EPS Actual
$0.14
EPS Est.
$0.01
EPS Surpr.
+1300.0%
Revenue
$0.08B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.31 | $0.32 | $0.32 | 1 |
| Q3 FY2027 | $0.27 | $0.28 | $0.28 | 1 |
| Q2 FY2027 | $0.26 | $0.26 | $0.27 | 1 |
| Q1 FY2027 | $0.22 | $0.23 | $0.23 | 1 |
| Q4 FY2026 | $0.17 | $0.17 | $0.17 | 1 |
| Q3 FY2026 | $0.18 | $0.19 | $0.19 | 3 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.1B | $0.1B | $0.1B | 3 |
| Q3 FY2027 | $0.1B | $0.1B | $0.1B | 2 |
| Q2 FY2027 | $0.1B | $0.1B | $0.1B | 2 |
| Q1 FY2027 | $0.1B | $0.1B | $0.1B | 3 |
| Q4 FY2026 | $0.1B | $0.1B | $0.1B | 3 |
| Q3 FY2026 | $0.1B | $0.1B | $0.1B | 4 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | Apr 28, 2026 | +209.1% | $21.85 | $21.91 | +0.27% |
| ▲ Q1 FY2026 | Feb 24, 2026 | +503.0% | $18.79 | $19.25 | +2.45% |
| ▲ Q4 FY2025 | Nov 4, 2025 | +115.4% | $14.77 | $14.52 | -1.69% |
| ▼ Q3 FY2025 | Aug 6, 2025 | -16.7% | $12.85 | $13.10 | +1.95% |
| ▲ Q2 FY2025 | Apr 30, 2025 | +50.0% | $18.13 | $16.88 | -6.89% |
| ▲ Q1 FY2025 | Feb 26, 2025 | +260.0% | $20.89 | $21.10 | +1.01% |
| ▲ Q4 FY2024 | Nov 4, 2024 | +1300.0% | $22.64 | $22.93 | +1.28% |
| ▲ Q3 FY2024 | Jul 31, 2024 | +292.3% | $18.76 | $19.99 | +6.56% |
Q2 FY2026+0.27%
Report Date
Apr 28, 2026
EPS Beat/Miss
+209.1%
Price Before
$21.85
Price After
$21.91
Q1 FY2026+2.45%
Report Date
Feb 24, 2026
EPS Beat/Miss
+503.0%
Price Before
$18.79
Price After
$19.25
Q4 FY2025-1.69%
Report Date
Nov 4, 2025
EPS Beat/Miss
+115.4%
Price Before
$14.77
Price After
$14.52
Q3 FY2025+1.95%
Report Date
Aug 6, 2025
EPS Beat/Miss
-16.7%
Price Before
$12.85
Price After
$13.10
Q2 FY2025-6.89%
Report Date
Apr 30, 2025
EPS Beat/Miss
+50.0%
Price Before
$18.13
Price After
$16.88
Q1 FY2025+1.01%
Report Date
Feb 26, 2025
EPS Beat/Miss
+260.0%
Price Before
$20.89
Price After
$21.10
Q4 FY2024+1.28%
Report Date
Nov 4, 2024
EPS Beat/Miss
+1300.0%
Price Before
$22.64
Price After
$22.93
Q3 FY2024+6.56%
Report Date
Jul 31, 2024
EPS Beat/Miss
+292.3%
Price Before
$18.76
Price After
$19.99
Avg Beat Reaction+0.43%
Avg Miss Reaction+1.95%
Beat Rate7 / 8 quarters
Largest Move-6.89% (Q2 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: CDNA ends December
CareDx, Inc (CDNA) most recently reported earnings on April 28, 2026 for Q2 FY2026, posting EPS of $0.34 — beating the analyst consensus of $0.11 by +209.1%. CDNA has beaten EPS estimates for 3 consecutive quarters. The next CDNA earnings date is expected around September 1, 2026.
Each quarter, investors track CDNA earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. CDNA revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
CDNA's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
CDNA earnings · 5 questionsCareDx, Inc's next earnings report is expected around September 1, 2026. CDNA typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; CDNA historically reports after market close (AMC).
CDNA earnings datewhen is CDNA earningsCDNA next earnings datewhen does CDNA report earningsCDNA earnings calendar
▸ Source: FMP · CareDx, Inc SEC filings · US GAAP · CareDx, Inc SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026